Leukemia SWOG 1117

March 13, 2013

Location: The Hospital of Central Connecticut

A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).